...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of alternative and complementary medicine: research on paradigm, practice, and policy >Efficacy and Safety of Ashwagandha Root Extract in Subclinical Hypothyroid Patients: A Double-Blind, Randomized Placebo-Controlled Trial
【24h】

Efficacy and Safety of Ashwagandha Root Extract in Subclinical Hypothyroid Patients: A Double-Blind, Randomized Placebo-Controlled Trial

机译：亚临床甲状腺功能亢进患者Ashwagandha根提取物的疗效和安全性：双盲，随机安慰剂对照试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Subclinical hypothyroidism, a thyroid disorder without obvious symptoms of thyroid deficiency, occurs in 3%–8% of the global population. Ashwagandha [ Withania somnifera (L.) Dunal] , a traditional medicine in Ayurveda, is often prescribed for thyroid dysfunctions. Objective: This pilot study was designed to evaluate the efficacy and safety of ashwagandha root extract in subclinical hypothyroid patients. Design, Setting, and Participants: A prospective, randomized, double-blind, single-center placebo-controlled study was performed at Sudbhawana Hospital, Varanasi, India between May 2016 and September 2016. Fifty subjects with elevated serum thyroid stimulating hormone (TSH) levels (4.5–10 μIU/L) aged between 18 and 50 were randomized in either treatment ( n = 25) or placebo ( n = 25) groups for an 8-week treatment period. Interventions: Ashwagandha root extract (600 mg daily) or starch as placebo. Efficacy Variables: Serum TSH, serum triiodothyronine (T3), and thyroxine (T4) levels. Results: A total of four subjects (two from each group) withdrew their consent before the second visit. Eight weeks of treatment with ashwagandha improved serum TSH ( p p = 0.0031), and T4 ( p = 0.0096) levels significantly compared to placebo. Ashwagandha treatment effectively normalized the serum thyroid indices during the 8-week treatment period in a significant manner (time-effects: TSH [ p p p Conclusion: Treatment with ashwagandha may be beneficial for normalizing thyroid indices in subclinical hypothyroid patients.
机译：背景：亚临床甲状腺功能减退症，没有明显甲状腺缺乏症状的甲状腺障碍，发生在全球人口的3％-8％。 Ashwagandha [含有Anaia Somnifera（L.）Dunal]，Ayurveda的传统医学通常是针对甲状腺功能障碍的规定。目的：这项试点研究旨在评估亚临床甲状腺功能率患者Ashwagandha根提取物的疗效和安全性。设计，设定和参与者：预期，随机，双盲，单中心安慰剂对照研究是在2016年5月至2016年5月至2016年5月之间的萨苏纳州萨拉纳斯医院进行的。血清甲状腺升高的血清升高（TSH）的五十个受试者在8周治疗期的治疗期间（n = 25）或安慰剂（n = 25）组中，在18和50岁之间的水平（4.5-10μIuu/l）在8周的治疗期间。干预措施：Ashwagandha根提取物（每日600毫克）或淀粉作为安慰剂。疗效变量：血清TSH，血清三碘甲酚（T3）和甲状腺素（T4）水平。结果：共有四名科目（每组两组）在第二次访问前撤回了同意。与Ashwagandha改善血清TSH（P P = 0.0031）和T4（P = 0.0096）水平与安慰剂相比，T4（P = 0.0096）水平的八周。 Ashwagandha治疗以显着的方式有效地将血清甲状腺指数有效化（时间效应：TSH [P P P P P：与Ashwagandha治疗可能有益于亚临床甲状腺功能亢进患者中的甲状腺指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号